112O - Primary result of an investigator-initiated phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study (NCCH1505)

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session New approaches in rare thoracic tumors
Topics Immunotherapy
Thymoma and Thymic Cancer
Thoracic Malignancies
Presenter Takashi Seto
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors T. Seto1, Y. Katsuya2, H. Horinouchi2, S. Umemura3, Y. Hosomi4, M. Satouchi5, A. Kuchiba2, Y. Ohe2
  • 1National Kyushu Cancer Center, 811-1395 - FUKUOKA/JP
  • 2National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4Department Of Thoracic Oncology & Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-0021 - Tokyo/JP
  • 5Hyogo Cancer Center, 673-8558 - Akashi/JP


Thymic carcinoma (TC) is a rare cancer with a poor prognosis. Treatment options are limited, especially after relapse. We previously reported that PD-L1 positivity was observed in 70% of TCs by immunohistochemistry suggesting anti PD-1/PD-L1 agents could be a promising treatment.